Performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Calculator in Rheumatoid Arthritis

Rheumatoid Arthritis

Disease activity predicts the development of cardiovascular events in patients with rheumatoid arthritis from the CARMA cohort

Semin Arthritis Rheum

Llorca J, Ferraz-Amaro I, Castañeda S, Plaza Z, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, González-Gay MÁ, CARMA Project Collaborative Group

doi: 10.1016/j.semarthrit.2025.152833

Psoriatic Arthritis

Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort

Semin Arthritis Rheum

Llorca J, Ferraz-Amaro I, Moreno-Martínez MJ, Plaza Z, Sánchez-Alonso F, Moreno-Ramos MJ, García-Gómez C, Castañeda S, González-Juanatey C, González-Gay MÁ, CARMA Project Collaborative Group

doi: 10.1016/j.semarthrit.2026.152923

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

The Fibrosis-4 Index (FIB-4) correlates with cardiovascular risk and insulin resistance in patients with rheumatoid arthritis

Rheumatology (Oxford)

Ferraz-Amaro I, Heras-Recuero E, de Vera-González A, González-Delgado A, Romo-Cordero A, Quevedo-Rodríguez A, Quevedo-Abeledo JC, Largo R, González-Gay MÁ

doi: 10.1093/rheumatology/keaf263

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Arthritis Rheumatol

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, Catlett IM, Maldonado MA, Wong R, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Fleischmann R

doi: 10.1002/art.70106

Rheumatoid Arthritis

Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts

Ann Rheum Dis

Derksen VFAM, Lindschou J, Winkel P, Delgado GE, de Moel EC, Huizinga TWJ, März W, Jakobsen JC, van der Helm-Van Mil AHM, Toes REM, Ajeganova S, Gluud C, Leipe J, van der Woude D, CLARICOR Trial Group and the LURIC Study Group

doi: 10.1016/j.ard.2025.11.023

Rheumatoid Arthritis

Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis

Rheumatology (Oxford)

Zhang Q, Qi Y, Wang X, McDermott GC, Chang SH, Chaballa M, Khaychuk V, Paudel ML, Sparks JA

doi: 10.1093/rheumatology/keaf380

Rheumatoid Arthritis

Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis

Ann Rheum Dis

Looijen AEM, Welsing PMJ, Bergstra SA, van der Helm-van Mil AHM, de Jong PHP

doi: 10.1016/j.ard.2025.11.019

Related content

Disease activity predicts the development of cardiovascular events in patients with rheumatoid arthritis from the CARMA cohort

Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

The Fibrosis-4 Index (FIB-4) correlates with cardiovascular risk and insulin resistance in patients with rheumatoid arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Inflammation rather than anticitrullinated protein antibodies is associated with cardiovascular mortality in RA: insights from rheumatoid arthritis and coronary artery disease cohorts

Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis

Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis